Article
Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
2024-02-15
Abstract excerpt
<h4>Background</h4> Reliable biomarkers for precision medicine in metastatic colorectal cancer (mCRC) are needed. Blood biomarkers like chemokines may offer insights into overall tumor burden, yet, few prospective studies explore chemokine dynamics during treatment. This study investigates the behavior of a chemokine panel in mCRC patients during first-line oxaliplatin-based treatment, aiming to identify predictiv...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 55c9fb85-0974-5345-91f6-98e42de21a1c
- DOI
- 10.1101/2024.02.15.24302875
